B2M and melanoma: The immunogenicity of these HLA-positive B2M gene-altered melanomas is still reduced to varying degrees, which means reduced T cell infiltration and decreased T cell–stimulatory capacity, and this confers an advantage for dissemination and expansion of those melanoma clones with irreversible genetic defects (29).